IDEAYA and GSK announce a broad partnership in Synthetic Lethality

This article was originally published here

The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years.  IDEAYA has solved

The post IDEAYA and GSK announce a broad partnership in Synthetic Lethality appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply